ImmunoCellular Therapeutics (IMUC)., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of various cancers.
IMUC’s lead product candidate is ICT-107, a dendritic cell (DC) immunotherapy targeting cancer stem cells (CSCs) and cancer antigens, which is in Phase III clinical trials for the treatment of glioblastoma
IMUC is also developing ICT-140, a DC-based immunotherapy targeting CSCs and cancer antigens that is in Phase I clinical trials for the treatment of ovarian cancer; and ICT-121, a DC-based immunotherapy targeting CD133 markers and CSCs, which is in Phase I clinical trials to treat recurrent GBM and other solid tumor cancers.
In addition, it has a portfolio of other potential therapeutic immunotherapies to treat cancer.
The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.
April 4, 2018
RegMed Investors’ (RMi) closing bell; relief rally and a rush to the upside
April 3, 2018
RegMed Investors’ (RMi) closing bell; sector flip-flops through-out the session
April 3, 2018
RegMed Investors’ (RMi) pre-open: cell therapy investment has been a heart breaker
April 2, 2018
RegMed Investors’ (RMi) closing bell; sector is technically broken
March 29, 2018
RegMed Investors’ (RMi) closing bell; an overdue rally
March 28, 2018
RegMed Investors’ (RMi) closing bell; the sector sputters and fails to rebound as …
March 27, 2018
RegMed Investors’ (RMi) closing bell; hammered and an all but a clean sweep of the sector
March 26, 2018
RegMed Investors’ (RMi) closing bell; the sector rallied at open, petered away and came back
March 23, 2018
RegMed Investors’ (RMi) closing bell; swing low, coming for to carry me down
March 22, 2018
RegMed Investors’ (RMi) closing bell; the sell-off returns
35 companies, 1 interpreter!
Insight, foresight and recommendation
ImmunoCellular Therapeutics (IMUC) -- Always a disappointment having oipened 1/2 at $0.34, cresting to $0.25 on 2/1 closing 2/16 at $0.24. Just another day traders toy ... it's also still in a research mode - stay away.
holdMy motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors